Erasca closed an upsized public offering that generated roughly $258.8 million in gross proceeds, the company said in a Globe Newswire filing. The financing sold 25.875 million shares at $10.00 each, including full exercise of the underwriters’ option. The cash boost supports Erasca’s clinical-stage oncology programs focused on RAS/MAPK pathway-driven cancers and funds near-term development and operations. Investors and analysts will watch upcoming trial milestones and how the company allocates proceeds toward accelerated data readouts and potential partnering.